Dr. Mike Graham Named Head of R&D at Bayer Crop Science Bayer has officially announced that Dr. Mike Graham will assume the role of Head of Research & Development (R&D) for Bayer’s Crop Science division. In this capacity, he will…
CEL-SCI: Multikine Boosts Quality of Life by Up to 95% in Head & Neck Cancer Patients CEL-SCI Corporation (NYSE American: CVM) has recently announced the publication of new data from its Phase 3 study of Multikine* (Leukocyte Interleukin, Injection) in…
Neurogene Announces Q4 & Full-Year 2024 Results, Updates Neurogene Inc., a clinical-stage company dedicated to developing life-changing genetic medicines for patients and families affected by rare neurological diseases, has announced its fourth quarter and full-year 2024 financial results along with…
Pearsanta Acquires Adductomics Tech for Cancer Risk Monitoring Aditxt, Inc. (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, has announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has completed the acquisition of key patents related to adductomics-based…
DNAnexus & AlidaBio Partner to Advance RNA Analysis DNAnexus, Inc., a leading provider of enterprise platforms for precision health data, has announced a strategic collaboration with Alida Biosciences (AlidaBio), a pioneer in RNA epigenomic research tools. This partnership aims to…
J&J Boosts U.S. Investment to $55B Over Four Years Johnson & Johnson, one of the world’s leading healthcare and pharmaceutical companies, has announced a significant increase in its investment in the United States. Over the next four years, the company…
AstraZeneca to Invest $2.5B in Beijing R&D, Biotech & Manufacturing AstraZeneca has announced a major investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre, alongside significant research and manufacturing agreements aimed at accelerating life sciences…
Omeros Updates Phase 3 Zaltenibart PNH Trial Omeros Corporation has announced that site activation for enrollment is underway in its Phase 3 clinical trial program evaluating zaltenibart (OMS906) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Zaltenibart is an investigational…
California University of Science and Medicine Celebrates 2025 MD Match Day California University of Science and Medicine (CUSM) proudly announced that its 2025 MD graduating class successfully secured residency placements as part of the national Match Day event. This milestone…
FDA Approves Alnylam’s AMVUTTRA® for ATTR-CM Treatment Alnylam Pharmaceuticals, Inc., a pioneer in RNAi therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for its RNAi-based therapeutic, AMVUTTRA® (vutrisiran). This…
Poxel Reports Positive Preclinical Results for PXL065 in HCM POXEL SA, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, has announced positive…
Verastem Oncology Q4 & Full-Year 2024 Results, Business Updates Verastem Oncology, a biopharmaceutical company dedicated to developing innovative therapies for cancer patients, has announced its financial results for the fourth quarter and full year ending December 31, 2024, along with…